top of page

Ulefnersen Phase 3 Clinical Trial Success Provides New Hope For ALS Patients

Sarah Dwyer
1 day ago
5 min read
Photo courtesy of Ionis Pharmaceuticals via WikiMedia Commons.
Photo courtesy of Ionis Pharmaceuticals via WikiMedia Commons.

On September 22, 2026, Ionis Pharmaceuticals and Otsuka Pharmaceutical announced that Ulefnersen, an experimental RNA-targeted therapy, successfully met the primary endpoint of its Phase 3 FUSION clinical trial. For decades, an amyotrophic lateral sclerosis (ALS) diagnosis has meant confronting a devastating reality: the progressive loss of the nerve cells responsible for movement, speech, and eventually, breathing. Despite years of research and increased funding, treatments capable of substantially altering the disease's course remain limited. Now, a promising clinical trial is offering a glimpse of what could be possible when scientists target the disease at its genetic source. 


ALS, commonly known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that destroys motor neurons. These specialized nerve cells are responsible for controlling voluntary movement. As these neurons deteriorate, patients gradually lose the ability to walk, speak, swallow, and breathe independently. ALS can arise spontaneously, without a known inherited mutation. Onset of the disease researchers have identified several genes associated with the disease. Among them is the protein fused in sarcoma (FUS), which encodes an RNA-binding protein involved in essential cellular processes.


Mutations in the FUS gene can disrupt normal protein function and contribute to abnormal protein accumulation, leading to motor neuron loss. According to a 2025 review published in The Lancet Neurology, FUS-associated ALS provides important insights into the molecular mechanisms underlying motor neuron disease. FUS-ALS accounts for approximately 0.6% of all ALS cases, but the condition is often particularly aggressive and disproportionately affects younger patients. The disease can progress rapidly, sometimes leading to respiratory failure within just one or two years of diagnosis.


Ulefnersen, previously known as ION363 or Jacifusen, takes a fundamentally different approach to treating the disease. Rather than attempting to restore motor function after neurons have already degenerated, the therapy aims to interfere with the production of the FUS protein implicated in disease progression. This treatment belongs to a class of therapeutics called antisense oligonucleotides (ASOs). These short, manufactured strands of nucleic acids bind to specific RNA sequences, allowing researchers to reduce the production of proteins associated with disease. By targeting FUS pre-messenger RNA, Ulefnersen promotes its degradation and reduces the production of FUS protein, including mutant forms associated with motor neuron toxicity. If successful, the treatment could slow disease progression by reducing a contributing molecular cause of degeneration before additional motor neurons are lost.


The drug demonstrated a statistically significant benefit in patients with FUS-associated ALS, a rare genetic form of the disease. The results indicate an important step toward a potential disease-modifying treatment for FUS-ALS. On a broader scale, the findings also reinforce an emerging direction in neurological medicine: targeting the molecular mechanisms responsible for neurodegeneration rather than exclusively managing its symptoms.


However, they also highlight a significant limitation: treatments targeting specific genetic mutations can benefit only the patients who carry those mutations. The vast majority of people living with ALS do not have FUS-associated disease. The challenge for researchers will be determining whether lessons from these therapies can inform treatments for other inherited forms of ALS and, eventually, the much larger population of patients with sporadic onset. There are also practical barriers to consider. Genetic testing, access to specialized neurological centers and the repeated intrathecal administration required by these therapies may complicate treatment delivery, particularly for patients who live far from major medical institutions. A scientific breakthrough can only translate into a meaningful public-health advance if patients can obtain the treatment.


The FUSION trial (NCT04768972) is a global, randomized, double-blind, placebo-controlled Phase 1-3 clinical study designed to evaluate the safety and effectiveness of Ulefnersen in people with FUS-ALS. During the study's 72-week double-blind treatment period, participants received either Ulefnersen or a placebo. The treatment was administered intrathecally: delivered directly into the cerebrospinal fluid surrounding the brain and spinal cord. The trial's primary endpoint evaluated both functional impairment and survival through a statistical approach known as a joint-rank analysis. Researchers combined several measures, including time to death or permanent ventilation, time to rescue treatment, and changes in the ALS Functional Rating Scale-Revised (ALSFRS-R).


The ALSFRS-R evaluates patients' abilities to perform activities such as walking, speaking, swallowing and breathing. Changes in these scores help researchers assess how the disease affects everyday functioning. According to the September 22 announcement, Ulefnersen demonstrated a statistically significant improvement on the primary composite endpoint compared with placebo, achieving a p-value of 0.0005 in a primary analysis population of 73 participants. The trial also demonstrated statistically significant benefits on important secondary endpoints, including changes in serum neurofilament light chain (NfL), a biomarker associated with neuronal injury.


The significance of the FUSION findings lies in the combination of clinical and biological outcomes. The results suggest that Ulefnersen may do more than alter a laboratory biomarker, it may also improve meaningful measures of disease progression. Still, the findings require careful interpretation. The results indicate strong evidence for treatment success, but they do not establish the magnitude of clinical benefit or the number of additional months patients might survive. The companies have released topline findings rather than a complete peer-reviewed analysis. Detailed results, including the size of the treatment effect and longer-term safety outcomes, will be critical to understanding Ulefnersen's full clinical potential.


Ulefnersen's success also contributes to a growing movement toward genetically targeted treatments for ALS. In April 2023, the U.S. Food and Drug Administration granted accelerated approval to Tofersen, marketed as Qalsody, an antisense therapy designed for patients with mutations in the superoxide dismutase 1 (SOD1) gene. Like Ulefnersen, Tofersen works by reducing overall production of a protein associated with a specific genetic subtype of ALS. The FDA based its accelerated approval on reductions in NfL, a biomarker reasonably likely to predict clinical benefit. Together, these developments illustrate the growing potential of precision medicine in neurodegenerative disease.


Ionis and Otsuka have announced plans to discuss the trials with the FDA and other international regulatory authorities, including the possibility of pursuing expedited approval pathways. For patients and families confronting FUS-ALS, these questions carry enormous weight. Even a treatment that slows, rather than reverses, neurodegeneration could preserve critical physical abilities and provide valuable additional time. More broadly, the FUSION results represent a meaningful advance in a field where translating molecular discoveries into effective treatments has historically proved difficult. The prospect of treating ALS at its genetic source is no longer isolated to laboratory experiments. Ulefnersen's Phase 3 results provide controlled clinical evidence that an RNA-targeted approach may change the trajectory of a devastating neurological disease. For a disease long defined by the progressive loss of function, the possibility of slowing that loss at its genetic origin represents a significant scientific step forward.


Comments


bottom of page